StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The discontinuation of PGN-EDO51 may lower investor confidence, causing PEPG's stock to drop.
What happened, with direct paths to the underlying reporting
PepGen discontinued PGN-EDO51 for Duchenne muscular dystrophy due to unsatisfactory results. Favorable safety profile observed, but dystrophin levels were inadequate. Focus will shift to advancing DM1 program with ongoing Phase 2 clinical trials. Upcoming data expected from FREEDOM-DM1 and FREEDOM2-DM1 studies in 2025 and 2026. PEPG stock fell 6.69% following the announcement.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.